Charting a bold path for diagnostics beyond the COVID blip: CEO of Genetic Signatures

Allison Rossiter, CEO of Genetic Signatures, is charting a bold new course for the ASX-listed infectious diseases company since taking the helm last September.

Despite the fact that over 70% of medical diagnoses and management decisions rely on pathology test results, Australia has been slow to adopt cutting-edge solutions. Rossiter pointed out the frustrating lag in the healthcare system when it comes to funding innovative pathology technologies.

“The fragmented system doesn’t help, but I think there is more at play,” Rossiter said. She cited examples in cancer and heart failure, where the Health Technology Assessment (HTA) “conservatism” is causing “harm”, at least in the short term.

She also shared her thoughts on the potential impact of U.S. Health Secretary Kennedy’s health overhaul on Australia’s regulatory framework, speculating on how such changes could influence the local system.

As the next federal election looms, both Federal Health Minister Mark Butler and Shadow Health Minister Senator Anne Ruston have underscored the importance of “prevention and early diagnosis” in shaping Australia’s healthcare priorities. However, do key policy commitments truly reflect this priority?

Given the vast number of stakeholders competing for airtime with policymakers, Rossiter addressed what needs to be done differently to drive timely access to advanced pathology technologies.

“This third cousin that people forget about is really important and it should be one of the front lines of healthcare,” she emphasised.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.